Navigation Links
AMS Announces Worldwide Launch of the Revolutionary MoXy™ Liquid Cooled Fiber for Fast, Safe Treatment of Enlarged Prostate
Date:9/30/2010

MINNETONKA, Minn., Sept. 30 /PRNewswire/ -- American Medical Systems® (AMS) (Nasdaq: AMMD), a leading provider of world-class devices and therapies for male and female pelvic health, today announced the worldwide launch of its revolutionary MoXy™ Liquid Cooled Fiber for laser treatment of benign prostatic hyperplasia (BPH) or enlarged prostate.

Designed to be used with the recently launched GreenLight XPS™ (Xcelerated Performance System) 180 Watt laser, the MoXy fiber, with its Active Cooling Cap™ technology, utilizes 360-degree saline flow to maintain the temperature of the fiber tip for dramatically increased fiber longevity. This combination is 50 percent faster in vaporization speed than the GreenLight HPS® (High Performance System) 120 Watt system, significantly reducing treatment time and operative cost. The new system maintains the same safety profile as the proven GreenLight HPS and PV systems, even with the increase in power.

The MoXy fiber is immediately available in the United States, Europe and Australia. Worldwide commercialization will continue throughout the remainder of 2010.

XPS with the MoXy fiber is the latest in AMS' world-class portfolio of innovative, technologically advanced solutions to treat a variety of pelvic health conditions. Through its commitment to innovation and continuous improvement, AMS has become the recognized technology leader in men's and women's pelvic health markets. For more information about GreenLight XPS and MoXy, visit www.AMSGreenLight.com.

About American Medical Systems:

American Medical Systems, headquartered in Minnetonka, Minnesota, is a diversified supplier of medical devices and procedures to cure incontinence, erectile dysfunction, benign prostatic hyperplasia (BPH), pelvic floor prolapse and other pelvic disorders in men and women. These disorders can significantly diminish one's quality of life and profoundly affect social relationships. In recent years, the number of people seeking treatment has increased markedly as a result of longer lives, higher quality-of-life expectations and greater awareness of new treatment alternatives. American Medical Systems' products reduce or eliminate the incapacitating effects of these diseases, often through minimally invasive therapies. The company's products were used to treat more than 335,000 patients in 2009.

More information about the company and its products can be found at www.AmericanMedicalSystems.com  and in the Company's Annual Report on Form 10-K for 2009 and its other SEC filings.


'/>"/>
SOURCE American Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... , Dec 9, 2016 Research and ... Market 2016-2020" report to their offering. ... The global travel vaccines market to ... The report covers the present scenario and the growth prospects ... market size, the report considers the revenue generated from the sales ...
(Date:12/8/2016)... Calif. , Dec. 8, 2016 IRIDEX Corporation ... to offer newly issued shares of common stock, $0.01 par ... to an underwritten public offering.  The final terms of the ... time of pricing, and there can be no assurance as ... IRIDEX expects to use the net proceeds it will ...
(Date:12/8/2016)... LONDON , Dec. 8, 2016  The global ... of 8.8% during the forecast period of 2016 to ... billion by 2021 from USD 18.21 billion in 2016. ... surgeries, rising incidences of sports related injuries and spinal ... and rising need of effective blood loss management. ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... ... LLC, announced the first national #QuackGivesBack campaign which supported local breast cancer ... our first franchise-wide Quack Gives Back initiative, and we’re very pleased ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s leading ... has aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced CURE ... Hennessy, Jr said, “CURE Media Group is honored to team up with Upstage Lung ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... modes of access for customers and employees that are both engaging and easy ... with Service Smart Technology, the software company revealed today its plans to roll ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased ... a convenient service for Texas, they are expanding their presence in Dallas. One of ... spree that will bring new jobs to the Dallas and Forth Worth market. STAT ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... Vida ... raised an $18M Series B led by Canvas Ventures . Other investors include ... to scale its mobile platform to serve more consumers who are managing chronic ...
Breaking Medicine News(10 mins):